On April 17, 2026, NEXGEL, INC. amended its Asset Purchase and Exclusive License Agreement with Celularity Inc., agreeing to pay $13.3 million, including $8.3 million in cash and a $5 million convertible note, for commercial-stage regenerative biomaterials. This represents a significant investment in their business strategy from an equity investor perspective.